The new biopharmaceutical blueprint
Pieter Deurinck, Kathleen Martin, Jay DiMare | IBM Institute for Business Value | 01-12-2007
Downloads: 234   Language: English
Detail
Hide
This white paper explores how a service-orientated architecture can bring flexibility to research and development (R&D) departments at pharmaceutical companies. These departments are under pressure to bring new treatments to market faster and extend their reach to global markets. Service-oriented architecture (SOA) can serve as the new blueprint for aligning business and IT.
1,28 MB | 21 Pages
Rating Rate this article
0,0/5,0
Bookmark
0
Comment Tell a friend Download

Message sent

Close
Your name: Friend name:
Your e-mail: Friend e-mail:

       
ARTICLE COMMENTS
Log in to comment article... 
Be the first to comment this article.

1de97f17-2389-4a75-a63e-bc58723861f3 Government. Open standards. The new biopharmaceutical blueprint Pieter Deurinck, Kathleen Martin, Jay DiMare Pieter Deurinck, Kathleen Martin, Jay DiMare IBM Institute for Business Value IBM Institute for Business Value 01-12-2007 1de97f17-2389-4a75-a63e-bc58723861f3" This white paper explores how a service-orientated architecture can bring flexibility to research and development (R&D) departments at pharmaceutical companies. These departments are under pressure to bring new treatments to market faster and extend their reach to global markets. Service-oriented architecture (SOA) can serve as the new blueprint for aligning business and IT.

MY BOOKMARKS


Please log in to create and see your bookmarks.